



InnoMatch

powered by
EIC INNOVATION PROCUREMENT PROGRAMME

Optomics®

supplier



buyer

 **bluepharma**



**Funded by
the European Union**

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.



InnoMatch

powered by

EIC INNOVATION PROCUREMENT PROGRAMME

About the solution

Optomics®

Optomics® is a cutting-edge AI-powered photonics platform that serves as a robust tool for analyzing lipid-based and polymeric nanoparticle formulations. Using simultaneous, label-free, and non-destructive multiparameter analysis, Optomics® addresses the current analytical gap left by conventional techniques, which are often destructive, slow, and limited to single-parameter outputs, delivering critical insights to reduce analysis time, enhance batch consistency monitoring, and provide richer datasets in a streamlined workflow.



Funded by
the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.



InnoMatch

powered by

EIC INNOVATION PROCUREMENT PROGRAMME

End-user

Within the **global pharmaceutical industry**, specifically major biopharmaceutical companies that specialize in innovative healthcare research and manufacturing.

The dream client profile specifically prioritizes organizations developing next-generation nanomedicines, where precise characterization is essential, but traditional, slow, and destructive analytical methods fall short. This also includes companies focused on mRNA and vaccines, where ensuring the stability and consistency of complex formulations is critical. Beyond therapeutics, this profile encompasses Contract Development and Manufacturing Organizations (CDMOs) that manage diverse project portfolios and need to accelerate client timelines while reducing sample waste across multiple product lines. Additionally, specialized biotech firms in oncology, gene therapy, and exosome research fit this profile due to their need for accurate characterization tools that preserve expensive, limited clinical materials.



Funded by
the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.



InnoMatch

powered by

EIC INNOVATION PROCUREMENT PROGRAMME

Interested? Get in touch.



ilof.tech

linkedin.com/company/iloftech

Learn more the pilot

innomatchproject.eu/pilots



**Funded by
the European Union**

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.